Lucid Diagnostics Secures First Commercial Insurance Coverage for EsoGuard® Esophageal DNA Test
New York, March 13, 2025 – Lucid Diagnostics Inc. (Nasdaq: LUCD), a medical diagnostics company focused on cancer prevention and a subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a significant achievement: Highmark Blue Cross Blue Shield has issued a positive coverage policy for the EsoGuard® Esophageal DNA Test. This marks the first commercial insurance coverage for the test.
This new policy covers non-invasive screening for esophageal precancer and cancer within New York state. Coverage applies to patients meeting established professional society guidelines for esophageal precancer testing. Lucid’s EsoGuard® test uses a non-invasive office procedure with its EsoCheck® Esophageal Cell Collection Device.
According to Dr. Lishan Aklog, Lucid’s Chairman and Chief Executive Officer, this coverage decision is a “landmark event” for the company. He elaborated, “We believe that this decision will serve as a precedent to drive positive policy coverage decisions from other commercial insurers and further validates the strength of our clinical evidence base. We remain deeply engaged with commercial insurers across the country as we seek to expand access to EsoGuard precancer testing.”
This positive policy coverage decision by a commercial insurer is a landmark event for Lucid.
This milestone is a critical step for Lucid Diagnostics. Dr. Aklog emphasized the company’s ongoing efforts to collaborate with other commercial insurers nationwide to broaden access to the EsoGuard pre-cancer test.
Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)
